Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER SOUNG

Allopathic & Osteopathic Physicians Dermatology

NPI
1346408226
CMS profile
151911
Location
SANTA ANA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$394,609.11

448 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $103,382.87 111
ABBVIE INC. $60,848.15 79
PFIZER INC. $56,365.53 32
Janssen Scientific Affairs, LLC $32,450.61 21
GENZYME CORPORATION $24,536.59 21
Regeneron Healthcare Solutions, Inc. $24,208.26 26
Janssen Biotech, Inc. $22,017.41 44
E.R. Squibb & Sons, L.L.C. $14,335.44 11
Incyte Corporation $13,096.69 15
Ortho Dermatologics, a division of Bausch Health US, LLC $9,987.35 16
LEO Pharma Inc. $8,936.45 16
Amgen Inc. $8,860.99 9
Eli Lilly and Company $5,269.86 11
Novartis Pharmaceuticals Corporation $5,266.90 21
UCB, Inc. $5,026.50 14
Helsinn Therapeutics (U.S.), Inc. $19.51 1

Page 2 of 9; records 51–100 of 448 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER SOUNG

NPI 1346408226 · CMS profile ID 151911

Allopathic & Osteopathic Physicians / Dermatology

SANTA ANA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 9; records 51–100 of 448 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346408226?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER SOUNG, NPI 1346408226, CMS profile ID 151911. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 448 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346408226?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JENNIFER SOUNG, NPI 1346408226, CMS profile ID 151911. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 448 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346408226?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JENNIFER SOUNG, NPI 1346408226, CMS profile ID 151911, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 448 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1346408226?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

448 matching records · $394,609.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 448 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 448.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $44.0011/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590539 CMS
Janssen Biotech, Inc. $9.0511/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590543 CMS
Janssen Biotech, Inc. $33.0411/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590547 CMS
Janssen Biotech, Inc. $16.0011/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590551 CMS
Lilly USA, LLC $1,200.0011/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918083347 CMS
Lilly USA, LLC $3,200.0011/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918106805 CMS
Janssen Biotech, Inc. $38.4011/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590567 CMS
Janssen Biotech, Inc. $50.0011/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590571 CMS
Janssen Biotech, Inc. $57.6011/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590575 CMS
Janssen Biotech, Inc. $716.4211/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590555 CMS
Janssen Biotech, Inc. $272.4611/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590559 CMS
Janssen Biotech, Inc. $175.9411/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590563 CMS
Janssen Biotech, Inc. $138.1511/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885590579 CMS
PFIZER INC. $3,500.0011/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949654509 CMS
Lilly USA, LLC $17.6111/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918126409 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $50.0411/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947505479 CMS
ABBVIE INC. $725.0011/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891646199 CMS
LEO Pharma Inc. $1,712.5011/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936290019 CMS
Novartis Pharmaceuticals Corporation $20.4111/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894396465 CMS
ABBVIE INC. $2,175.0011/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891646197 CMS
Regeneron Healthcare Solutions, Inc. $70.0011/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927420047 CMS
Regeneron Healthcare Solutions, Inc. $13.7511/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927420054 CMS
ABBVIE INC. $725.0011/07/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891646195 CMS
PFIZER INC. $4.5211/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949605961 CMS
GENZYME CORPORATION $109.5511/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939011987 CMS
Novartis Pharmaceuticals Corporation $18.2811/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894396461 CMS
ABBVIE INC. $1,087.5011/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891646193 CMS
Lilly USA, LLC $94.6711/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918128539 CMS
Regeneron Healthcare Solutions, Inc. $1,901.0011/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927420037 CMS
LEO Pharma Inc. $2,670.0011/02/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936290009 CMS
LEO Pharma Inc. $141.5511/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936290015 CMS
E.R. Squibb & Sons, L.L.C. $18.5211/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932531651 CMS
GENZYME CORPORATION $1,725.0011/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939011997 CMS
PFIZER INC. $3,500.0011/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949604893 CMS
Novartis Pharmaceuticals Corporation $4.3510/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894396453 CMS
Novartis Pharmaceuticals Corporation $2.1310/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894396457 CMS
Janssen Scientific Affairs, LLC $2,860.0010/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887187211 CMS
Regeneron Healthcare Solutions, Inc. $3,743.0010/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927420029 CMS
UCB, Inc. $700.0010/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908099987 CMS
ABBVIE INC. $543.7510/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891646191 CMS
Lilly USA, LLC $16.0010/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918083327 CMS
Lilly USA, LLC $41.0010/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918086373 CMS
Lilly USA, LLC $125.0010/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918086375 CMS
Lilly USA, LLC $10.0010/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918106785 CMS
Lilly USA, LLC $40.0010/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918126381 CMS
Lilly USA, LLC $56.1010/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918128533 CMS
Lilly USA, LLC $60.0010/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918156943 CMS
ABBVIE INC. $25.9410/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891646189 CMS
E.R. Squibb & Sons, L.L.C. $300.0010/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932531673 CMS
LEO Pharma Inc. $9.3610/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936290003 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $316,849.45 419
PY2020 $182,323.11 205
PY2021 $271,237.24 287
PY2022 $394,609.11 448
PY2023 $518,842.87 560
PY2024 $595,867.53 617
PY2025 $490,895.92 537

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,356.76 4
PY2025 Principal investigator $988,790.42 131
PY2024 Recipient $5,410.00 4
PY2024 Principal investigator $1,115,200.17 403
PY2023 Recipient $9,880.00 12
PY2023 Principal investigator $777,498.70 155
PY2022 Recipient $3,122.00 3
PY2022 Principal investigator $710,481.87 72
PY2021 Recipient $259.00 1
PY2021 Principal investigator $1,284,621.55 124
PY2020 Recipient $2,449.80 2
PY2020 Principal investigator $1,267,758.63 139
PY2019 Recipient $15,369.36 4
PY2019 Principal investigator $1,338,754.61 120

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $18,997.00 12/31/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202535239
Principal investigator 1 Janssen Research & Development, LLC $1,981.00 12/25/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442063
Principal investigator 1 Janssen Research & Development, LLC $4,212.00 12/25/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442148
Principal investigator 1 Janssen Research & Development, LLC $5,943.00 12/19/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442069
Recipient PFIZER INC. $3,200.00 12/18/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810886
Principal investigator 1 SANOFI US SERVICES INC. $16,263.00 12/08/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084212
Principal investigator 1 ABBVIE INC. $6,455.70 12/04/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202527620
Principal investigator 1 Janssen Research & Development, LLC $5,914.00 12/01/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442037
Principal investigator 1 Janssen Research & Development, LLC $3,538.00 12/01/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442081
Principal investigator 1 ABBVIE INC. $5,197.22 11/05/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521481
Principal investigator 1 Janssen Research & Development, LLC $3,928.00 11/03/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442130
Recipient Amgen Inc. $1,886.76 10/29/2025 Covered Recipient Physician A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD No dispute reported 06/30/2026 1246636952
Principal investigator 1 Novartis Pharmaceuticals Corporation $105,039.05 10/28/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307153
Principal investigator 1 SANOFI US SERVICES INC. $23,446.00 10/27/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084183
Principal investigator 1 Janssen Research & Development, LLC $5,914.00 10/24/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442075
Principal investigator 1 ABBVIE INC. $10,516.12 10/09/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202514393
Principal investigator 1 Janssen Research & Development, LLC $3,538.00 09/29/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442109
Principal investigator 1 Janssen Research & Development, LLC $4,212.00 09/29/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442118
Principal investigator 1 Janssen Research & Development, LLC $4,671.00 09/29/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442141
Principal investigator 1 PFIZER INC. $1,550.00 09/11/2025 Non-covered Recipient Entity
J Robert West MD Inc
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228707974
Principal investigator 1 Janssen Research & Development, LLC $7,175.00 09/08/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442136
Principal investigator 1 SANOFI US SERVICES INC. $12,054.00 09/08/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084126
Principal investigator 1 ABBVIE INC. $10,752.50 09/04/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509952
Principal investigator 1 Janssen Research & Development, LLC $4,334.00 09/04/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442015
Recipient PFIZER INC. $940.00 08/29/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810913
Principal investigator 1 PFIZER INC. $1,550.00 08/11/2025 Non-covered Recipient Entity
J Robert West MD Inc
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228707970
Principal investigator 1 ABBVIE INC. $5,433.60 08/06/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503351
Principal investigator 1 SANOFI US SERVICES INC. $7,596.00 08/04/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084097
Principal investigator 1 Janssen Research & Development, LLC $2,966.00 07/28/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442086
Principal investigator 1 Janssen Research & Development, LLC $19,271.00 07/28/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442154
Principal investigator 1 PFIZER INC. $1,550.00 07/16/2025 Non-covered Recipient Entity
J Robert West MD Inc
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228707794
Principal investigator 1 PFIZER INC. $1,550.00 07/16/2025 Non-covered Recipient Entity
J Robert West MD Inc
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228707972
Principal investigator 1 SANOFI US SERVICES INC. $19,920.00 07/14/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084073
Principal investigator 1 ABBVIE INC. $7,224.52 07/08/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497446
Principal investigator 1 Janssen Research & Development, LLC $7,113.00 06/27/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442166
Principal investigator 1 Janssen Research & Development, LLC $6,299.00 06/26/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442170
Principal investigator 1 Eli Lilly and Company $46,367.00 06/19/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187886008
Principal investigator 1 SANOFI US SERVICES INC. $65,084.00 06/16/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084048
Principal investigator 1 Janssen Research & Development, LLC $2,171.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179590
Principal investigator 1 Janssen Research & Development, LLC $1,668.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179613
Principal investigator 1 Janssen Research & Development, LLC $312.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179621
Principal investigator 1 Janssen Research & Development, LLC $2,769.80 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179658
Principal investigator 1 Janssen Research & Development, LLC $362.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179719
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179730
Principal investigator 1 Janssen Research & Development, LLC $2,769.80 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179743
Principal investigator 1 Janssen Research & Development, LLC $1,668.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179752
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179795
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179803
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179827
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179845
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179881
Principal investigator 1 Janssen Research & Development, LLC $2,171.40 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179889
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179917
Principal investigator 1 Janssen Research & Development, LLC $3,374.80 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179924
Principal investigator 1 Janssen Research & Development, LLC $1,668.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179933
Principal investigator 1 Janssen Research & Development, LLC $603.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179955
Principal investigator 1 Janssen Research & Development, LLC $3,374.80 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179963
Principal investigator 1 Janssen Research & Development, LLC $2,769.80 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179997
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180012
Principal investigator 1 Janssen Research & Development, LLC $2,171.40 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180034
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180050
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180067
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180075
Principal investigator 1 Janssen Research & Development, LLC $1,668.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180107
Principal investigator 1 Janssen Research & Development, LLC $1,667.60 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180114
Principal investigator 1 Janssen Research & Development, LLC $2,769.80 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180167
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180207
Principal investigator 1 Janssen Research & Development, LLC $2,171.00 06/04/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180215
Principal investigator 1 ABBVIE INC. $7,346.20 06/03/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488773
Principal investigator 1 PFIZER INC. $12,435.00 05/29/2025 Non-covered Recipient Entity
J Robert West MD Inc
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228840023
Principal investigator 1 SANOFI US SERVICES INC. $13,300.00 05/27/2025 Non-covered Recipient Entity
J Robert West M D Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226084041
Principal investigator 1 Janssen Research & Development, LLC $2,879.00 05/26/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442057
Principal investigator 1 Janssen Research & Development, LLC $2,371.00 05/22/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442031
Principal investigator 1 ABBVIE INC. $19,752.60 05/07/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483937
Principal investigator 1 ABBVIE INC. $1,890.90 05/06/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202482185
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838482
Principal investigator 1 Janssen Research & Development, LLC $3,323.00 04/28/2025 Non-covered Recipient Entity
Sthrn California Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175180090
Principal investigator 1 Janssen Research & Development, LLC $6,002.00 04/28/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442044
Principal investigator 1 Janssen Research & Development, LLC $2,879.00 04/28/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442124
Principal investigator 1 SANOFI US SERVICES INC. $5,107.00 04/21/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226084020
Principal investigator 1 ABBVIE INC. $8,702.88 04/03/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202470982
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 04/02/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083992
Principal investigator 1 SANOFI US SERVICES INC. $3,256.00 04/02/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226084003
Principal investigator 1 Janssen Research & Development, LLC $6,938.00 03/27/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442098
Principal investigator 1 Janssen Research & Development, LLC $10,939.00 03/24/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442024
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179598
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179630
Principal investigator 1 Janssen Research & Development, LLC $4,557.30 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179668
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179684
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179693
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179708
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179812
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179835
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179865
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179898
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179942
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179989
Principal investigator 1 Janssen Research & Development, LLC $4,557.30 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180026
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180058
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180081
Principal investigator 1 Janssen Research & Development, LLC $218.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180097
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180122
Principal investigator 1 Janssen Research & Development, LLC $201.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180128
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180136
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180147
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180153
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180190
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180198
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180233
Principal investigator 1 Janssen Research & Development, LLC $574.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180240
Principal investigator 1 Janssen Research & Development, LLC $156.00 03/12/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180258
Principal investigator 1 ABBVIE INC. $15,363.12 03/07/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459874
Principal investigator 1 ABBVIE INC. $2,121.90 03/06/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202456897
Principal investigator 1 Janssen Research & Development, LLC $48,232.00 03/05/2025 Non-covered Recipient Entity
Sthrn California Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175179677
Principal investigator 1 SANOFI US SERVICES INC. $14,908.00 03/04/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226084000
Principal investigator 1 Janssen Research & Development, LLC $6,646.00 03/03/2025 Non-covered Recipient Entity
Sthrn California Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175180174
Principal investigator 1 Janssen Research & Development, LLC $11,830.00 03/03/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442051
Principal investigator 1 Janssen Research & Development, LLC $2,777.00 03/03/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442177
Principal investigator 1 Janssen Research & Development, LLC $2,541.00 02/27/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179640
Principal investigator 1 Janssen Research & Development, LLC $2,541.00 02/27/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179777
Principal investigator 1 Janssen Research & Development, LLC $2,541.00 02/27/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179872
Principal investigator 1 Janssen Research & Development, LLC $2,541.00 02/27/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175179982
Principal investigator 1 Janssen Research & Development, LLC $9,759.00 02/07/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442160
Principal investigator 1 ABBVIE INC. $13,405.11 02/06/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202449286
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 02/05/2025 Non-covered Recipient Entity
Sthrn California Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175179909
Principal investigator 1 Janssen Research & Development, LLC $343.00 02/05/2025 Non-covered Recipient Entity
Sthrn California Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175179973
Principal investigator 1 SANOFI US SERVICES INC. $7,095.00 02/04/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083980
Principal investigator 1 Janssen Research & Development, LLC $2,541.00 01/27/2025 Non-covered Recipient Entity
J Robert W MD Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175180005
Principal investigator 1 SANOFI US SERVICES INC. $14,300.00 01/27/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083976
Principal investigator 1 Janssen Research & Development, LLC $6,372.00 01/24/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442093
Principal investigator 1 SANOFI US SERVICES INC. $81,174.00 01/24/2025 Non-covered Recipient Entity
J Robert West M D Inc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083972
Principal investigator 1 Janssen Research & Development, LLC $10,057.00 01/16/2025 Non-covered Recipient Entity
Sthrn California Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175179702
Principal investigator 1 Janssen Research & Development, LLC $22,870.00 01/09/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175442103
Principal investigator 1 Eli Lilly and Company $53,964.70 01/07/2025 Non-covered Recipient Entity
J ROBERT WEST MD INC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187883756
Principal investigator 1 ABBVIE INC. $1,851.90 01/02/2025 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202435689